Muutke küpsiste eelistusi

Essentials of Pharmacoeconomics [Pehme köide]

3.76/5 (50 hinnangut Goodreads-ist)
  • Formaat: Paperback / softback, 250 pages, kõrgus x laius: 254x178 mm, kaal: 408 g, 44
  • Ilmumisaeg: 11-Feb-2008
  • Kirjastus: Lippincott Williams and Wilkins
  • ISBN-10: 0781765447
  • ISBN-13: 9780781765442
Teised raamatud teemal:
  • Pehme köide
  • Hind: 76,15 €*
  • * saadame teile pakkumise kasutatud raamatule, mille hind võib erineda kodulehel olevast hinnast
  • See raamat on trükist otsas, kuid me saadame teile pakkumise kasutatud raamatule.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Lisa soovinimekirja
Essentials of PharmacoeconomicsSuurem pilt
  • Formaat: Paperback / softback, 250 pages, kõrgus x laius: 254x178 mm, kaal: 408 g, 44
  • Ilmumisaeg: 11-Feb-2008
  • Kirjastus: Lippincott Williams and Wilkins
  • ISBN-10: 0781765447
  • ISBN-13: 9780781765442
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9780781765442.html
Märksõnad:

This new text is designed for a student or practitioner who is unfamiliar with "pharmacoeconomics." It provides a straightforward explanation of the essential pharmacoeconomics topics outlined by The Accreditation Council for Pharmacy Education (ACPE). It defines terminology used in research and covers the application of economic-based evaluation methods for pharmaceutical products and services. Readers will find examples of how pharmacoeconomic evaluations relate to decisions that affect patient care and health-related quality of life.



Essentials of Pharmacoeconomics is designed for a student or practitioner who is unfamiliar with "pharmacoeconomics." It introduces the fundamental topics, defines the terminology used in pharmacoeconomic research, and gives many examples in evaluating published research so readers can evaluate literature relevant to their practice. It guides readers to understand, interpret, apply, and determine the usefulness of pharmacoeconomic research articles.
Part I Basic Topics
Introduction
1(8)
Pharmacoeconomics---What Is It?
2(1)
Why is Pharmacoeconomics Important?
2(1)
Relationship of Pharmacoeconomics to Other Research
3(1)
Types of Pharmacoeconomic Studies
4(3)
Summary
7(1)
Questions/Exercises
7(1)
References
8(1)
Suggested Readings
8(1)
Measuring and Estimating Costs
9(16)
Costing Terms
10(1)
Cost Categorization
10(2)
Alternative Method of Categorization
12(1)
Perspective
13(1)
Timing Adjustments for Costs
13(4)
Resources for Cost Estimations
17(5)
Summary
22(1)
Questions/Exercises
22(1)
References
23(1)
Suggested Readings
23(2)
Critiquing Research Articles
25(10)
Appropriateness of Methods of Analysis
26(1)
Questions to Use When Critiquing Research Articles
26(6)
Summary
32(1)
Questions/Exercises
32(1)
References
33(1)
Suggested Readings
34(1)
Cost-Minimization Analysis
35(12)
Overview of Cost-Minimization Analysis
36(1)
Summary
37(1)
Composite Article: CMA
38(5)
Questions/Exercises
43(2)
Reference
45(1)
Suggested Readings
45(2)
Cost-Effectiveness Analysis
47(20)
Overview of Cost-Effectiveness Analysis
48(1)
Presentation of Costs and Effectiveness
48(1)
Cost-Effectiveness Grid
49(2)
Cost-Effectiveness Plane
51(4)
Intermediate Outcomes versus Primary Outcomes
55(1)
Efficacy versus Effectiveness
56(1)
Consensus and Debate
56(1)
Summary
57(1)
Composite Article: CEA
57(8)
Questions/Exercises
65(1)
References
65(1)
Suggested Readings
65(2)
Cost-Utility Analysis (CUA)
67(22)
Overview of Cost-Utility Analysis
68(1)
Steps in Calculating QALYs
68(5)
Summary
73(5)
Composite Article: CUA
78(7)
Questions/Exercises
85(1)
References
86(1)
Suggested Readings
87(2)
Cost-Benefit Analysis
89(22)
Definition and History
90(1)
Advantages and Disadvantages of Cost-Benefit Analysis
90(1)
Conducting a Cost-Benefit Analysis
91(1)
Difference Between Costs Versus Benefits
92(1)
Measuring Indirect and Intangible Benefits
93(5)
Calculating Results of Costs and Benefits
98(2)
Summary
100(1)
Composite Article: CBA
101(7)
Questions/Exercises
108(1)
References
109(1)
Suggested Readings
109(2)
Health-Related Quality of Life: Health Status Measures
111(24)
Definitions
112(1)
Health-Related Quality of Life: Utility Measures versus Health Status Measures
112(3)
Domains of Health Status
115(2)
Assessing Health Status Instruments
117(2)
Pharmacoeconomics and Health Status Measures
119(1)
Patient-Reported Outcomes
120(1)
Summary
120(1)
Composite Article: HRQOL
121(7)
Questions/Exercises
128(4)
References
132(2)
Suggested Readings
134(1)
PART II Advanced Topics
Decision Analysis
135(20)
What is Decision Analysis?
136(1)
Steps in Decision Analysis
136(4)
Threshold Analysis
140(3)
Summary
143(2)
Composite Article: Decision Analysis
145(7)
Questions/Exercises
152(1)
References
153(1)
Suggested Readings
153(2)
Markov Modeling
155(22)
Overview of Markov Modeling
156(1)
Steps in Markov Modeling
156(6)
Disadvantages of Markov Modeling
162(1)
Advanced Issues
163(1)
Summary
164(1)
Composite Article: Markov Modeling
165(8)
Questions/Exercises
173(2)
References
175(1)
Suggested Readings
175(2)
Retrospective Databases
177(20)
Overview of Retrospective Databases
178(1)
Randomized, Controlled Trials
178(1)
Observational Studies
178(1)
Advantages and Disadvantages of Randomized, Controlled Trials
178(1)
Advantages and Disadvantages of Observational Studies
179(2)
Types of Retrospective Databases
181(3)
Critiquing Retrospective Database Studies
184(1)
Summary
185(1)
Composite Article: Retrospective Database
186(7)
Questions/Exercises
193(1)
References
194(1)
Suggested Readings
195(2)
Pharmacy Services
197(20)
What Are Pharmacy Services?
198(1)
History of Pharmacy Services
198(1)
Review of the Research
198(3)
Issues in Valuing Pharmacy Services
201(1)
Medicare Medication Therapy Management
202(2)
Summary
204(1)
Composite Article: Pharmacy Services
205(7)
Questions/Exercises
212(1)
References
213(2)
Suggested Readings
215(2)
International Perspective
217(10)
Health Care Expenditures
218(1)
Comparability of Pharmacoeconomic Results Between Countries
218(1)
History of Pharmacoeconomic Guideline Development
218(5)
Summary
223(1)
Questions/Exercises
224(1)
References
225(1)
Suggested Readings
226(1)
Future Issues
227(10)
Application of Pharmacoeconomics in the United States
228(1)
Federal Agencies
228(1)
Private Health Care Plans
229(1)
Barriers to Pharmacoeconomics in the United States
230(1)
Other Future Issues
231(2)
Summary
233(1)
Questions/Exercises
234(1)
References
234(1)
Suggested Readings
235(2)
Glossary 237(6)
Index 243